A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

Astellas

Status: Completed

Conditions: Bipolar Disorder; Depression

Treatments: Drug: Quetiapine

Study type: Observational

Funder types: Industry

Identifiers

NCT03403790

6949-MA-3199

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.

Full description

This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.

Enrollment: 369 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with depressive symptoms of bipolar disorder
• Patients who have previously not been treated with quetiapine fumarate (immediate-release formulations of quetiapine fumarate and Bipresso Extended-Release Tablets)

Exclusion criteria

• None

Trial design

369 participants in 1 patient group

Patients with depression in bipolar disorder

Description:

Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time

Treatment:

Drug: Quetiapine